New Cardiac Troponin Submissions Will Have To Meet Revised Standards
This article was originally published in The Pink Sheet Daily
Executive Summary
Assays on the market today were cleared under an outdated standard that no longer represents clinical practice, leaving a gap between how they are used and what they are validated to measure.
You may also be interested in...
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: